Vince Calio

Investigators are optimistic about sacituzumab govitecan (IMMU-132), an antibody–drug conjugate that delivers the chemotherapy metabolite SN-38 to tumor cells expressing the TROP-2 receptor, for patients with relapsed/refractory TNBC.

Robert J. Kreitman, MD, discusses key attributes of moxetumomab pasudotox and its potential impact in hairy cell leukemia.

There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.